Robust RSV Surveillance Data Will be Key to Getting US Clinicians Comfortable with New Adult Vaccine

"We are going to need to invest in more robust surveillance systems. Truly what we are missing with RSV is a firm understanding of just how pervasive it is, how often it's responsible for hospitalizations."

The US Food and Drug Adminstration recently approved the world's first vaccine against respiratory syncytial virus (RSV), this formulation targeting adults aged ≥60 years.

Kelly Moore, MD, MPH, president and chief executive officer of Immunize.org, has extensive experience with large scale immunization campaigns and spoke with Patient Care^®about what education and communication strategies will need to focus on for US health care practitioners to become comfortable allocating resources to administer the new vaccine.

Kelly Moore, MD, MPH, is the president and chief executive officer of Immunize.org, a nonprofit immunization education and advocacy organization that supports state and local immunization coalitions and front-line immunization providers. She also is adjunct associate professor of health policy at Vanderbilt University School of Medicine. Until 2018, Moore served as the director of the Tennessee Immunization Program at the state's department of health. She has served as a voting member of the Advisory Committee on Immunization Practices of the Centers for Diseaes Conrol and Prevention and is an advisor to the World Health Organization. Moore is board certified in preventive medicine and public health.